• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis (Small 11/2022)
Breast Cancer TreatmentIn article number2107550, Wassana Yantasee and co-workers develop polymer-decorated mesoporous silica nanoparticles for HER2-positive breast cancer treatment. This patented versatile platform can co-deliver multiple therapeutic classes to ensure that they reach the target cells at the same time to fully realize their synergy. Illustrated herein are nanoparticles with three drug cargos: HER2 antibody, HER2 siRNA, and chemotherapeutic docetaxel.
Source: Small - March 17, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Cover Picture Source Type: research

Targeted Nanoparticle for Co ‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis
This research paper describes a new therapeutic candidate based on a nanoparticle that co-delivers siRNA against human epidermal growth factor receptor type 2 (HER2), trastuzumab, and docetaxel to treat advanced HER2+ breast cancer. The nanotherapeutic is more effective and safer than the free drug counterparts. It inhibits drug-resistant orthotopic and brain-metastatic HER2+ breast tumors in mice. AbstractThe first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or pacli...
Source: Small - January 27, 2022 Category: Nanotechnology Authors: Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz ‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee Tags: Research Article Source Type: research

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
Abstract Glycoprotein nonmetastatic B (GPNMB) is a potential oncogene that is particularly expressed in melanoma and breast cancer (BC). To clarify its clinical significance in BC, we measured serum GPNMB in vivo and investigated its cross talk with human epidermal growth factor 2 (HER2). GPNMB was expressed in four of six breast cell lines (SK‐BR‐3, BT‐474, MDA‐MD‐231, and MDA‐MD‐157), two of six colorectal cell lines, and two of four gastric cancer (GC) cell lines. We established a GPNMB quantification system using enzyme‐linked immunosorbent assay (ELISA) for these cell lines. We measured serum GPNMB in...
Source: Cancer Medicine - June 16, 2015 Category: Cancer & Oncology Authors: Masako Kanematsu, Manabu Futamura, Masafumi Takata, Siqin Gaowa, Atsuko Yamada, Kasumi Morimitsu, Akemi Morikawa, Ryutaro Mori, Hideaki Hara, Kazuhiro Yoshida Tags: Original Research Source Type: research

Abstract P5-05-11: Growth hormone receptor silencing sensitizes triple negative breast cancer cells to chemotherapy
In this study we investigated the impact of GHR silencing in TNBC cells and further analyzed the possible mechanisms associated with GHR silencing induced sensitization. GHR was silenced using small interfering RNAs in metastatic breast cancer cells MDA MB 231 and MDA MB 468. Molecular analyses were performed to determine apoptosis, cytotoxicity, colony formation, invasion and migration in GHR knockdown cells. Silencing of GHR induced cytotoxicity and apoptosis in TNBC cells. Migratory and invasive potentials were drastically reduced in GHR silenced cells. Moreover, epithelial to mesenchymal transition markers were signifi...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Arumugam, A., Subramani, R., Nandy, S., Lopez-Valdez, R., Lakshmanaswamy, R. Tags: Poster Session Abstracts Source Type: research